Advances in Epigenomic Sequencing and Their Applications in Cancer Diagnostics
Authors:
Open Access
- 21 May 2025
- journal article
- Published by American Chemical Society (ACS) in Precision Chemistry
- Vol. 3 (10) , 581-603
Abstract
Cancer, a globally prevalent and life-threatening disease, remains a major area of focus in biomedical research. However, its substantial heterogeneity and complex pathogenesis continue to pose significant challenges for accurate diagnosis and effective treatment. The rapid advancement of epigenomic sequencing technologies has opened avenues by uncovering the epigenetic hallmarks and underlying pathology of cancer. As a result, these technologies have become invaluable tools in advancing cancer diagnostics and connecting research with clinical applications. This review briefly overviews epigenomic modifications and their significance in cancer diagnostics, highlighting potential epigenomic biomarkers with clinical applicability. We also examine emerging techniques in bulk and single-cell sequencing approaches, alongside spatial tools, highlighting their integration with multiomics technologies for cancer diagnostics. Particular attention is given to the analysis of key epigenetic characteristics, such as DNA methylation, histone modifications, and chromatin accessibility. Additionally, we summarize the diagnostic applications of these technologies and evaluate their current adoption in clinical settings. Challenges, limitations, and future directions for advancing epigenomic sequencing toward routine clinical diagnostics are also discussed. This review aims to provide scientists and clinicians with a comprehensive resource, encouraging further exploration and adoption of epigenomic sequencing technologies to drive progress in precision medicine.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL173271)
- Yale School of Medicine
- National Institute of General Medical Sciences (R35 GM150838)
This publication has 199 references indexed in Scilit:
- Evaluation of combined detection of multigene mutation and SDC2/SFRP2 methylation in stool specimens for colorectal cancer early diagnosisInternational Journal of Colorectal Disease, 2022
- A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinomaHepatology Communications, 2022
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation setAnnals of Oncology, 2021
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- A cross‐sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor‐derived DNA with CEA for detection of recurrent colorectal cancerCancer Medicine, 2016
- Cancer Epigenetics: An Introduction2014
- Isolation of Active Regulatory Elements from Eukaryotic Chromatin Using FAIRE (Formaldehyde‐Assisted Isolation of Regulatory Elements)2011
- Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assayBreast Cancer Research and Treatment, 2011
- Global levels of histone modifications predict prostate cancer recurrenceThe Prostate, 2009
- Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer developmentGenes, Chromosomes and Cancer, 2008